Claims for Patent: 8,883,964

Summary for Patent: 8,883,964

Title:	Compositions comprising modified collagen and uses therefor
Abstract:	The invention provides modified collagen and related therapeutic and diagnostic methods.
Inventor(s):	Yu; Michael (Timonium, MD), Elisseeff; Jennifer H. (Baltimore, MD), Wang; Allen Yi-Lan (Vienna, VA), Lee; Hyeseung Janice (Washington, DC), Mo; Xiao (Lutherville, MD)
Assignee:	The Johns Hopkins University (Baltimore, MD)
Application Number:	13/605,534
Patent Claims:	1. A collagen mimetic peptide conjugate, wherein the peptide is an amino acid sequence selected from the group consisting of: Gly.sub.3-(ProHypGly).sub.6 (SEQ ID NO: 13), Gly.sub.3-(ProHypGly).sub.7 (SEQ ID NO: 14), Gly.sub.3-(ProHypGly).sub.8 (SEQ ID NO: 15), Gly.sub.3-(ProHypGly).sub.9 (SEQ ID NO: 16), (ProHypGly).sub.6-Tyr (SEQ ID NO: 17), (ProHypGly).sub.7-Tyr (SEQ ID NO: 18), (ProHypGly).sub.8-Tyr (SEQ ID NO: 19), Cys-(Pro-Hyp-Gly).sub.3 (SEQ ID NO: 20), Cys-(Pro-Hyp-Gly).sub.5 (SEQ ID NO: 21), and Cys-(Pro-Hyp-Gly).sub.7 (SEQ ID NO: 22), and wherein the conjugate is selected from the group consisting of a cell adhesion molecule, a detectable label, a growth factor, a component of the extracellular matrix, a polymer, polyethylene glycol (PEG), and a small molecule. 2. The collagen mimetic peptide conjugate of claim 1, wherein the peptide comprises: carboxyfluorescein-Gly.sub.3-(Pro-Hyp-Gly).sub.9 (SEQ ID NO: 23), carboxyfluorescein-Gly.sub.3-1ys-(Pro-Hyp-Gly).sub.8 (SEQ ID NO: 24), PEG.sub.2000-Gly.sub.3-(Pro-Hyp-Gly).sub.7 (SEQ ID NO: 25), Methoxy PEG.sub.2000-Gly.sub.3-(Pro-Hyp-Gly).sub.7 (SEQ ID NO: 6), (Pro-Hyp-Gly).sub.8-Gly.sub.3-PEG.sub.5000-OH (SEQ ID NO: 26), [AcGly-Gly.sub.2-Lys-Gly.sub.3-(Pro-Hyp-Gly).sub.8].sub.4-star shaped PEG (core sequence disclosed as SEQ ID NO: 27), [CF-Gly.sub.3-Lys-Gly.sub.3-(Pro-Hyp-Gly).sub.8].sub.4-star shaped PEG (core sequence disclosed as SEQ ID NO: 28), AcGly-Gly.sub.2-Lys-Gly.sub.3-(Pro-Hyp-Gly).sub.8 (SEQ ID NO: 29), FL-PEG.sub.2000-Gly.sub.3-(Pro-Hyp-Gly).sub.7 (SEQ ID NO: 30), and 5 carboxyfluorescein-Gly.sub.3(Pro-Hyp-Gly).sub.8-Gly.sub.3-PEG.sub.5000-OH (SEQ ID NO: 31). 3. The collagen mimetic peptide conjugate of claim 1, wherein the detectable label is 5-carboxy-fluorescein. 4. The collagen mimetic peptide conjugate of claim 1, wherein the cell adhesion molecule is selected from the group consisting of a cadherin, fibronectin, integrin, laminin, and selectin. 5. The collagen mimetic peptide conjugate of claim 1, wherein the detectable label is selected from the group consisting of a colloidal particle, an enzyme, an electron- dense reagent, a fluorescent dye, a hapten, an immunogen, a magnetic bead, and a radiolabel, gadolinium complex, gadodiamide derivative, ferric ammonium citrate, or mangafodipar trisodium. 6. The collagen mimetic peptide conjugate of claim 1, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, and cell survival. 7. The collagen mimetic peptide conjugate of claim 1, wherein the component of the extracellular matrix is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparin sulfate, heparin, keratan sulfate, and aggrecan. 8. The collagen mimetic peptide conjugate of claim 1, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2-hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol. 9. The collagen mimetic peptide conjugate of claim 1, wherein the PEG is selected from the group consisting of a star shaped PEG, a multi-armed PEG, a graft linear PEG. 10. The collagen mimetic peptide conjugate of claim 1, wherein the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, and cartilage repair agents. 11. The collagen mimetic peptide conjugate of claim 10, wherein the anti-thrombotic is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP, TenectaplaseCMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab-CMP, Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP. 12. The collagen mimetic peptide conjugate of claim 10, wherein the antiatherosclerosis agent is selected from the group consisting of heparin-CMP, Hirudin- CMP, SaratinCMP, Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, AbciximabCMP, Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP. 13. The collagen mimetic peptide conjugate of claim 10, wherein the cartilage repair agent is chondroitin sulfate.

Details for Patent 8,883,964

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2024-11-23